Plasma ceramides and cardiovascular events in hypertensive patients at high cardiovascular risk

CONCLUSIONS: A ceramide-based CERT-HBP was established to evaluate risk of MACE in hypertensive patients at high cardiovascular risk. This may improve identification of high-risk patients requiring increased attention and aggressive therapy.PMID:34232291 | DOI:10.1093/ajh/hpab105

Source: American Journal of Hypertension - July 7, 2021 Category: Cardiology Authors: Wenjie Yin Fengjuan Li Xin Tan Huimin Wang Wenxi Jiang Xue Wang Sijin Li Yanbo Zhang Qinghua Han Yuan Wang Jie Du Source Type: research